Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Deals

Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases

Fineline Cube Sep 6, 2023

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...

Company Drug

Neurophth Biotechnology’s NFS-05 Gene Therapy Gets Australian Clinical Trial Approval for ADOA

Fineline Cube Sep 6, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that it has received clinical trial...

Company Deals

MGI Tech Partners with Eight Companies to Expand G99-Based Sequencing Applications

Fineline Cube Sep 6, 2023

China-based MGI Tech, a subsidiary of BGI Group (SHE: 300676), has entered into cooperation agreements...

Company Drug

Harbin Gloria Pharmaceuticals’ Zimberelimab Receives NMPA Approval for Cervical Cancer Treatment

Fineline Cube Sep 6, 2023

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has announced that it has received market...

Company

Janssen Appoints Cherry Huang as President of Xi’an Janssen in China Management Shake-Up

Fineline Cube Sep 6, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced a significant management...

Company Drug

Seagen and Genmab Announce Positive Phase III Results for Tivdak in Cervical Cancer

Fineline Cube Sep 5, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), and...

Company Drug

SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis

Fineline Cube Sep 5, 2023

Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...

Company

Weight-Loss Drug Demand Pushes Novo Nordisk to Peak European Market Capitalization

Fineline Cube Sep 5, 2023

Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) achieved a significant milestone last week when it...

Company Legal / IP

Janssen Sues Distributors Over Counterfeit Antiretroviral Therapies in the US

Fineline Cube Sep 5, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, filed a lawsuit last week against pharmaceutical...

Company Drug

Columbia University Study Weighs Cost-Effectiveness of Weight-Loss Treatments for Adolescents

Fineline Cube Sep 5, 2023

Researchers at US Columbia University have published the results of a study estimating the cost-effectiveness...

Company

Shanghai Pharmaceuticals Executives Under Investigation for Serious Disciplinary Violations

Fineline Cube Sep 5, 2023

China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has disclosed that several...

Company Drug

BDgene Technology Announces Clinical Milestone for CRISPR-Cas9 Gene Therapy in HSK

Fineline Cube Sep 5, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced the conclusion of three clinical...

Company

Sanofi Announces Management Restructuring with New Leadership Roles in China

Fineline Cube Sep 5, 2023

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced a significant restructuring of its management structure...

Company Deals

ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO

Fineline Cube Sep 5, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock...

Company Drug

Sihuan Pharmaceutical’s Birociclib NDA Accepted for Review by China’s NMPA

Fineline Cube Sep 5, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that the National Medical Products...

Company Deals

Bloomage Biotech Terminates Joint Venture with Medytox Inc. for Botulinum Toxin Development

Fineline Cube Sep 5, 2023

China-based Bloomage Biotech (SHA: 688363) has revealed that a termination agreement has been signed with...

Company Drug

Jointown Medical’s COVID-19 Drug Candidate SHEN211 Accepted for Review by NMPA

Fineline Cube Sep 5, 2023

China-based Jointown Medical Devices Group Co., Ltd (SHA: 600998) has announced that its clinical trial...

Company Drug

Hansoh Pharmaceutical Receives NMPA Approval for Generic Ofev (Nintedanib)

Fineline Cube Sep 5, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received marketing...

Company Deals

Pilot Gene Technology Secures $13.8 Million in Series B Financing for Diagnostic Expansion

Fineline Cube Sep 4, 2023

China-based diagnostic reagents specialist, Pilot Gene Technology (Hangzhou) Co., Ltd, has reportedly raised RMB 100...

Company Drug

Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026

Fineline Cube Sep 4, 2023

The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version...

Posts pagination

1 … 481 482 483 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.